Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World tracking: can this MS drug slow disability progression?

NCT ID NCT05376579

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study observed 134 adults in Italy with active secondary progressive multiple sclerosis (MS) who were newly starting the drug Mayzent (siponimod) as part of their regular care. Over three years, researchers tracked whether the drug helped slow the worsening of physical and mental disability, reduced relapses, and improved quality of life. The goal was to understand the real-world, long-term effects of this treatment on controlling the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Ancona, AN, 60126, Italy

  • Novartis Investigative Site

    L’Aquila, AQ, 67100, Italy

  • Novartis Investigative Site

    Bergamo, BG, 24127, Italy

  • Novartis Investigative Site

    Bologna, BO, 40124, Italy

  • Novartis Investigative Site

    Brescia, BS, 25123, Italy

  • Novartis Investigative Site

    Como, CO, 22100, Italy

  • Novartis Investigative Site

    Catanzaro, CZ, 88100, Italy

  • Novartis Investigative Site

    Foggia, FG, 71122, Italy

  • Novartis Investigative Site

    Genova, GE, 16132, Italy

  • Novartis Investigative Site

    Messina, ME, 98124, Italy

  • Novartis Investigative Site

    Milan, MI, 20133, Italy

  • Novartis Investigative Site

    Palermo, PA, 90127, Italy

  • Novartis Investigative Site

    Padua, PD, 35128, Italy

  • Novartis Investigative Site

    Pisa, PI, 56126, Italy

  • Novartis Investigative Site

    Pavia, PV, 27100, Italy

  • Novartis Investigative Site

    Roma, RM, 00133, Italy

  • Novartis Investigative Site

    Roma, RM, 00152, Italy

  • Novartis Investigative Site

    Roma, RM, 00189, Italy

  • Novartis Investigative Site

    Orbassano, TO, 10043, Italy

  • Novartis Investigative Site

    Trieste, TS, 34149, Italy

  • Novartis Investigative Site

    Vicenza, VI, 36100, Italy

  • Novartis Investigative Site

    Napoli, 80131, Italy

  • Novartis Investigative Site

    Napoli, 80138, Italy

  • Novartis Investigative Site

    Novara, 28100, Italy

Conditions

Explore the condition pages connected to this study.

ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS